Visus Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Visus Therapeutics's estimated annual revenue is currently $3.7M per year.
- Visus Therapeutics's estimated revenue per employee is $77,500
- Visus Therapeutics's total funding is $56M.
Employee Data
- Visus Therapeutics has 48 Employees.
- Visus Therapeutics grew their employee count by 12% last year.
Visus Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO, Executive Director | Reveal Email/Phone |
2 | Chief Medical Officer and Head R&D | Reveal Email/Phone |
3 | VP, Human Resources | Reveal Email/Phone |
4 | VP, Pharmaceutical Development | Reveal Email/Phone |
5 | VP Information Technology | Reveal Email/Phone |
6 | VP Marketing | Reveal Email/Phone |
7 | VP Pharmaceutical Development | Reveal Email/Phone |
8 | VP, Clinical Operations and Compliance | Reveal Email/Phone |
9 | Associate VP, Project & Portfolio Management | Reveal Email/Phone |
10 | VP | Reveal Email/Phone |
Visus Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Visus Therapeutics?
Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle, WA and Irvine, CA., our lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma, and age-related macular degeneration.
keywords:N/A$56M
Total Funding
48
Number of Employees
$3.7M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Visus Therapeutics News
Visus Therapeutics launched the first of two pivotal Phase III Trials for Brimochol PF for presbyopia. Presbyopia is loss of near vision...
Visus Therapeutics kicks off Phase 3 pivotal trial for presbyopia treatment ... The company has dosed the first patients in a Phase 3 trial...
With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.6M | 48 | 0% | N/A |
#2 | $9.7M | 48 | 4% | N/A |
#3 | $1.7M | 48 | 7% | N/A |
#4 | $5.6M | 48 | N/A | N/A |
#5 | $5.6M | 48 | N/A | N/A |